Evidence map›Paper›PMID 27092279›Full record

ArticleProstate cancer2016

Salvage Brachytherapy for Biochemically Recurrent Prostate Cancer following Primary Brachytherapy.

John M Lacy, William A Wilson, Raevti Bole, Li Chen, Ali S Meigooni, Randall G Rowland, William H St Clair

Open access · goldAbstract read
In one paragraph

Article in Prostate cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Linac-based stereotactic salvage reirradiation for intraprostatic prostate cancer recurrence: toxicity and outcomes.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2023
    Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

John M LacyDepartment of Urology, University of Kentucky College of Medicine, Lexington, KY 40536, USA.
William A WilsonDepartment of Radiation Oncology, University of Kentucky College of Medicine, Lexington, KY 40536, USA.
Raevti BoleUniversity of Kentucky College of Medicine, Lexington, KY 40536, USA.
Li ChenDepartment of Biostatistics, University of Kentucky College of Public Health, Lexington, KY 40536, USA.
Ali S MeigooniComprehensive Cancer Centers of Nevada, Las Vegas, NV 89169, USA.
Randall G RowlandDepartment of Urology, University of Kentucky College of Medicine, Lexington, KY 40536, USA.
William H St ClairDepartment of Radiation Oncology, University of Kentucky College of Medicine, Lexington, KY 40536, USA.
University of Kentucky · USComprehensive Cancer Centers of Nevada · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose. In this study, we evaluated our experience with salvage brachytherapy after discovery of biochemical recurrence after a prior brachytherapy procedure. Methods and Materials. From 2001 through 2012 twenty-one patients treated by brachytherapy within University of Kentucky or from outside centers developed biochemical failure and had no evidence of metastases. Computed tomography (CT) scans were evaluated; patients who had an underseeded portion of their prostate were considered for reimplantation. Results. The majority of the patients in this study (61.9%) were low risk and median presalvage PSA was 3.49 (range 17.41-1.68). Mean follow-up was 61 months. At last follow-up after reseeding, 11/21 (52.4%) were free of biochemical recurrence. There was a trend towards decreased freedom from biochemical recurrence in low risk patients (p = 0.12). International Prostate Symptom Scores (IPSS) increased at 3-month follow-up visits but decreased and were equivalent to baseline scores at 18 months. Conclusions. Salvage brachytherapy after primary brachytherapy is possible; however, in our experience the side-effect profile after the second brachytherapy procedure was higher than after the first brachytherapy procedure. In this cohort of patients we demonstrate that approximately 50% oncologic control, low risk patients appear to have better outcomes than others.

Identifiers

PMID27092279
PMCPMC4820628
OpenAlexW2311265951

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.